Oncology Advisory Board is another potential catalyst

Just remembering this statement from the March Letter to Shareholders, "To accelerate progress in oncology where feasible, we’re establishing an oncology advisory board to ensure we are exploring the fastest and most responsible pathway(s) forward." With so many indications in solid tumor/metastatic cancers, I believe the board will include some heavy hitters and could be a catalyst for the stock. This announcement can come at any moment, since it's unrelated to the ESMO poster and could provide a nice set-up ahead of the conference.